In chronic lymphocytic leukaemia, SLAMF1 deregulation is associated with genomic complexity and independently predicts a worse outcome.

Autor: Rigolin, Gian Matteo, Saccenti, Elena, Melandri, Aurora, Cavallari, Maurizio, Urso, Antonio, Rotondo, Francesco, Betulla, Anita, Tognolo, Lucia, Bardi, Maria Antonella, Rossini, Marika, Tammiso, Elisa, Bassi, Christian, Cavazzini, Francesco, Negrini, Massimo, Cuneo, Antonio
Předmět:
Zdroj: British Journal of Haematology; Mar2021, Vol. 192 Issue 6, p1068-1072, 5p
Abstrakt: Summary: In a series of 349 patients with chronic lymphocytic leukaemia (CLL), we found lower levels of signalling lymphocytic activation molecule family member 1 (SLAMF1) expression in cases with highly complex karyotypes, as defined by the presence of five or more chromosomal abnormalities (CK5; P < 0·001) and with major chromosomal structural abnormalities (P < 0·001). SLAMF1 downregulation was significantly associated with advanced Binet Stage (P = 0·001), CD38 positivity (P < 0·001), high β2‐microglobulin levels (P < 0·001), immunoglobulin heavy chain variable region gene (IGHV) unmutated status (P < 0·001), 11q deletion (P < 0·001), tumour protein p53 (TP53) disruption (P = 0·011) and higher risk CLL International Prognostic Index categories (P < 0·001). Multivariate analysis showed that downregulated SLAMF1 levels had independent negative prognostic impact on time‐to‐first treatment (P < 0·001) and overall survival (P < 0·001). [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index